Prometrium Standard Titration Schedule

What Is the Standard Prometrium Titration Schedule?

The FDA-approved starting point is 100 mg of micronized progesterone at bedtime. For endometrial protection in postmenopausal women on conjugated estrogen, the label specifies 200 mg nightly for 12 consecutive days per 28-day cycle. Titration therefore moves from 100 mg (an off-label starting dose many prescribers use to test tolerability) to the 200 mg label dose once sedation, dizziness, and gastrointestinal effects are confirmed to be acceptable.

Real-world prescribing commonly starts below the labeled 200 mg ceiling to reduce the likelihood of early discontinuation caused by pronounced sedation. The Endocrine Society's 2022 menopause guidelines note that patient tolerability, not pharmacokinetic targets alone, should govern pace of escalation in hormone therapy [1].

The Two FDA-Labeled Dose Regimens

The Prometrium prescribing information describes two distinct dosing regimens, each tied to a clinical goal [2]:

• Endometrial protection (continuous combined HRT): 200 mg at bedtime for 12 days of a 28-day cycle, taken alongside daily conjugated estrogen 0.625 mg.
• Secondary amenorrhea: 400 mg at bedtime for 10 days.

Continuous daily regimens (100 mg or 200 mg every night without a break) are used extensively in clinical practice, particularly for women who prefer to avoid scheduled withdrawal bleeding, though these regimens carry a higher rate of irregular spotting in the first 3 to 6 months of use [3].

Starting at 100 mg Versus 200 mg

The 100 mg starting approach rests on the sedative pharmacology of micronized progesterone. Oral absorption converts a portion of the dose to allopregnanolone, a potent GABA-A receptor positive modulator [4]. At 200 mg, allopregnanolone levels rise high enough to cause meaningful next-morning sedation in roughly 30% of patients in controlled studies [5]. Beginning at 100 mg for four weeks lets the patient adapt neurologically before the dose doubles.

How Quickly Can You Increase Prometrium?

Most clinicians allow 4 to 12 weeks between dose steps. The pace depends on three factors: endometrial protection adequacy, side-effect burden, and the reason progesterone is being used.

The 4-Week Minimum

One complete treatment cycle (or one full calendar month for continuous users) is the practical minimum before escalation. Allopregnanolone-mediated sedation tends to diminish substantially within 2 to 4 weeks as GABA-A receptor downregulation occurs [4]. Escalating before 4 weeks means the patient's side-effect profile at the new dose is being evaluated on top of a nervous system that has not yet adjusted to the starting dose.

The 12-Week Ceiling for Reassessment

If a patient remains on 100 mg for longer than 12 weeks without adequate endometrial protection being demonstrated (confirmed by absence of breakthrough bleeding or by sonographic endometrial stripe <4 mm), a step up to 200 mg is clinically indicated. Prolonged under-dosing of the progestogen component in a woman with an intact uterus on estrogen carries real risk. The PEPI trial (N=875) demonstrated that unopposed estrogen produced complex or atypical endometrial hyperplasia in 34% of participants over 3 years, compared with fewer than 1% in the cyclic micronized progesterone arm [6].

When Faster Escalation Is Appropriate

Women presenting with confirmed endometrial hyperplasia, persistent breakthrough bleeding on 100 mg, or high baseline estrogen doses (e.g., estradiol 2 mg or higher daily) may need to move to 200 mg within 4 weeks under close clinical supervision. The FDA label for Prometrium does not prohibit faster escalation; it specifies target doses rather than minimum uptitration intervals [2].

Pharmacokinetics That Drive the Titration Logic

Understanding why titration matters requires a brief look at how oral micronized progesterone behaves in the body.

Oral Bioavailability and First-Pass Metabolism

Oral bioavailability is approximately 10% [2]. The liver and intestinal wall reduce a large fraction of the absorbed dose to inactive and active metabolites, including allopregnanolone and pregnanolone. This first-pass effect means that small changes in absorption conditions produce disproportionate changes in peak plasma levels (Cmax). A high-fat meal raises the area under the concentration-time curve by roughly 45% and Cmax by approximately 80% compared with fasting [2]. The FDA label recommends taking Prometrium with food for more consistent absorption, but bedtime dosing after a light snack is the standard clinical compromise between the food-effect recommendation and sedation management.

Half-Life and Steady-State

The elimination half-life ranges from 16 to 18 hours after a single 200 mg oral dose [2]. Steady-state plasma concentrations are reached within 2 to 3 days of continuous daily dosing. This short half-life is one reason cyclic regimens (12 days on, 16 days off) produce measurable endometrial differentiation: the progestogen effect is concentrated rather than diluted across a full month [7].

Sedation Peak and Its Timing

Peak allopregnanolone levels occur approximately 1 to 2 hours after oral ingestion. Sedation is most pronounced between hours 2 and 4 post-dose [5]. Bedtime administration exploits this window. Prescribers who inadvertently counsel morning or midday dosing see a much higher dropout rate, which is a dosing error rather than a drug failure.

Cyclic Versus Continuous Titration Protocols

The two dominant prescribing patterns differ in more than convenience. Each carries a distinct titration pathway and a different set of monitoring requirements.

Cyclic Protocol (Sequential Combined HRT)

In cyclic dosing, progesterone is added to estrogen for 12 to 14 consecutive days each month. Titration follows this sequence:

1. Cycle 1 to 3: 100 mg at bedtime for 12 days. Monitor for sedation, dizziness, breast tenderness, and the character of any withdrawal bleed.
2. Cycle 4 onward: Step up to 200 mg at bedtime for 12 days if the 100 mg dose does not produce adequate withdrawal bleeding or if breakthrough bleeding occurs outside the progesterone window.

The PEPI trial used 200 mg for 12 days without a 100 mg lead-in phase [6]. In clinical practice, that full-dose start is reasonable for patients with no prior progesterone sensitivity and no history of GABA-A-related sedation problems.

Continuous Protocol (Continuous Combined HRT)

Daily progesterone without a scheduled break is preferred by many peri- and postmenopausal women who want to avoid monthly withdrawal bleeding. Irregular spotting is common in the first 3 to 6 months; this is not an indication to escalate the dose prematurely [3].

Titration for continuous use:

1. Months 1 to 3: 100 mg every night.
2. Month 4 onward: Escalate to 200 mg nightly if spotting persists beyond 6 months or if sonographic endometrial stripe exceeds 4 mm.

A 2020 observational study of 312 postmenopausal women on continuous micronized progesterone found that 78% achieved amenorrhea by month 6 on 100 mg nightly, with the remaining 22% achieving amenorrhea after escalation to 200 mg [3].

Managing Side Effects During Titration

Side effects at each titration step determine whether escalation proceeds on schedule, slows down, or requires a dose reduction.

Sedation and Cognitive Effects

Next-morning drowsiness affects roughly 24% of patients on 200 mg in the first month of therapy [5]. At 100 mg, the rate is closer to 10 to 15%. Strategies that reduce sedation without sacrificing endometrial protection include:

• Strict bedtime timing (10 to 11 PM or immediately before sleep).
• Avoiding alcohol within 4 hours of the dose, since ethanol potentiates GABA-A agonism.
• Temporary dose reduction back to 100 mg if safety concerns (e.g., operating machinery early in the morning) arise.

Dizziness and Falls

Older patients (65 and above) carry a meaningfully higher fall risk from progesterone-induced vestibular effects [2]. The FDA label includes a specific warning. In this population, escalation beyond 100 mg should be assessed at each step against the documented fall-risk benefit of lower dosing.

Breakthrough Bleeding

Unexpected bleeding during titration is the most common reason clinicians reassess the dose rather than simply escalate it. Bleeding that occurs during the progestogen phase of a cyclic regimen suggests adequate endometrial response. Bleeding that occurs outside the progestogen window suggests either inadequate dose or inadequate cycle length. Escalation of dose duration (from 12 days to 14 days) is sometimes tried before dose escalation [7].

PEPI Trial Evidence and What It Tells Prescribers

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial remains the foundational RCT for micronized progesterone titration decisions. Published in JAMA in 1995, PEPI enrolled 875 postmenopausal women and randomized them to placebo, unopposed conjugated estrogen 0.625 mg, or one of three combined hormone regimens over 3 years [6].

The cyclic micronized progesterone arm used 200 mg for 12 days per cycle alongside conjugated estrogen 0.625 mg daily. Key findings relevant to titration:

• Endometrial hyperplasia occurred in fewer than 1% of women in the cyclic micronized progesterone arm versus 34% with unopposed estrogen (P<0.001) [6].
• HDL-cholesterol was better preserved in the micronized progesterone arm than in the medroxyprogesterone acetate arm, suggesting a cardiovascular-profile advantage.
• No dose-escalation protocol was embedded in PEPI; the trial used the full 200 mg dose from the start.

The PEPI data establish that 200 mg for 12 days reliably protects the endometrium. What the trial does not answer is whether 100 mg for 12 days provides equivalent protection. That gap is where the HealthRX Clinical Framework for Prometrium Titration applies: a structured decision tree mapping symptom burden, endometrial stripe measurements, and bleeding pattern to a recommended titration step. This framework should be inserted by the editorial team at review.

Monitoring Parameters Across Titration Phases

Careful monitoring ensures each dose step achieves its goal without causing harm.

Endometrial Monitoring

• Transvaginal ultrasound (TVUS) at baseline for any postmenopausal woman before starting combined HRT [8].
• Repeat TVUS if unscheduled bleeding occurs at any titration step.
• Endometrial biopsy if stripe thickness exceeds 4 mm on a continuous regimen or if bleeding is heavy or prolonged [8].

The American College of Obstetricians and Gynecologists recommends biopsy for postmenopausal bleeding regardless of hormone therapy status [8].

Laboratory and Clinical Monitoring

• Blood pressure at each visit (progesterone has minimal direct effect, but estrogen can affect cardiovascular parameters).
• Sleep quality and daytime alertness questionnaire at 4 weeks and 12 weeks post-escalation.
• Breast examination and mammography per standard screening guidelines; progesterone exposure duration is factored into breast tissue density changes [9].

Mood and Neurological Monitoring

Micronized progesterone's GABA-A agonism can have mood effects that differ from synthetic progestogens. Some women report improved sleep and reduced anxiety on low-dose oral progesterone; others report depressive symptoms at higher doses [10]. A standardized mood scale (e.g., PHQ-9) administered at each titration step allows objective tracking. If PHQ-9 scores worsen by 5 or more points, a dose review is warranted before further escalation.

Special Populations: Titration Adjustments

Perimenopausal Women

Progesterone levels fluctuate widely in perimenopause. Women still cycling irregularly may need progesterone only during the luteal phase or in 12-day pulses aligned with irregular cycles. Starting at 100 mg for 12 days in any cycle where progesterone is indicated is the standard approach; escalation to 200 mg follows the same 4-to-12-week framework [1].

Women With Prior Progesterone Sensitivity

A personal history of severe premenstrual dysphoric disorder or luteal-phase mood disruption signals likely sensitivity to allopregnanolone. For these patients, some clinicians start at 50 mg (a compounded dose or a half-capsule of the 100 mg formulation) for 4 weeks before advancing to 100 mg [10]. FDA-approved Prometrium comes in 100 mg and 200 mg capsules only; the 50 mg starting point requires either halving a 100 mg capsule or using a compounding pharmacy.

Women on High-Dose Estrogen

Estradiol doses above 1 mg orally daily or 0.05 mg transdermally produce higher circulating estrogen levels that drive more endometrial proliferation. These women may need to begin titration at 200 mg rather than 100 mg, or to extend the progestogen phase from 12 to 14 days per cycle [7].

Drug Interactions That Affect Titration Decisions

Several common drug classes alter progesterone metabolism and may shift the effective dose at each titration step.

CYP3A4 Inducers

Rifampin, carbamazepine, phenytoin, and St. John's Wort accelerate hepatic CYP3A4 activity, reducing progesterone plasma levels by 30 to 50% [2]. A patient started on 100 mg while taking rifampin may need 200 mg to achieve equivalent endometrial protection. This interaction should be documented before the first dose is selected, not discovered during a titration plateau.

CYP3A4 Inhibitors

Ketoconazole, clarithromycin, and grapefruit juice slow progesterone clearance. On these agents, the 100 mg dose may produce plasma levels equivalent to 150 to 180 mg without the interaction [2]. Escalation in the presence of a strong inhibitor should be done with extra caution; monitoring for amplified sedation is the key clinical signal.

Anticoagulants

Progesterone does not directly affect warfarin's INR in most patients, but any new hormone addition should prompt INR recheck within 2 to 4 weeks in women on warfarin, per standard prescribing practice [2].